20% Salicylic Acid Peel
Originaltext auf Französisch.
20% Salicylic Acid Peel, NPN 80072016: in Kanada zugelassenes Naturgesundheitsprodukt. Medizinische Inhaltsstoffe: Acide 2-hydroxybenzoïque.
Die Analyse oraler Dosen ist ohne einen nachgewiesenen ausschließlich oralen Verabreichungsweg nicht anwendbar.
Zusammensetzung
| Arzneilicher Inhaltsstoff und Quelle | Je Dosiseinheit laut Quelle |
|---|---|
| Acide 2-hydroxybenzoïque Quelle : Acide salicylique | 20 % |
Nicht arzneiliche Inhaltsstoffe
Propanediol, SD alcool 40-B, Glycyrrhétinate de stéaryle, Dimethyl isosorbide, Hydroxyde de sodium, Eau
In Kanada empfohlene Dosen
| Bevölkerungsgruppe | Alter | Menge pro Einnahme | Häufigkeit |
|---|---|---|---|
| Adultes | Non précisée | Non précisée | Non précisée |
In Kanada zugelassene Verwendungen
Contributes to reduce the signs of chronic photo aging, by helping skin renewal. Helps to correct skin discoloration, by renewing the surface of the skin. For the treatment/management of acne. Helps treat acne pimples (Optional: "and allow skin to heal"). Dries and helps clear up acne pimples (Optional: "and allow skin to heal"). Reduces the number and/or severity of acne pimples (Optional: "and allow skin to heal"). Penetrates pores to help control (reduce) acne pimples. Helps keep skin clear of new acne pimples. Helps prevent new acne pimples from forming.
Originaltext auf Englisch.
Eine in Kanada zugelassene Verwendung ist keine in der Europäischen Union zugelassene gesundheitsbezogene Angabe. Beachten Sie das Register gesundheitsbezogener Angaben.
Warnhinweise in Kanada
Contre-indications : Do not use on inflamed, irritated, reddened or broken skin. Not for use on individuals who are pregnant or breastfeeding, have diabetes, vitiligo, poor blood circulation, a herpetic breakout, open wounds, suspicious lesions, severely dry skin, currently suffer from any type of infection, are sensitive to aspirin/salicylic acid, have received recent chemotherapy or radiation therapy, used isotretinoin in the past 12 months or are taking photosensitizing medication.
Originaltext auf Französisch.
Effets indésirables connus : Some people may experience a burning sensation, dermatitis, swelling, or blisters.
Originaltext auf Französisch.
Précautions et mises en garde : Use only as directed. For Professional Use Only. Not for Retail Sale. For external use only. Keep out of reach of children. Patient should be explained the risks associated with this product prior to administration. Test product on a small area of the patient's skin, before applying to the whole area to be treated. If application causes severe discomfort or irritation, wash the area immediately with cold water and discontinue use. If irritation persists, consult a health care practitioner. If a severe reaction occurs (e.g. chemical burn, hives/blistering, swelling of eyes/mouth, blistering or difficulty breathing), seek immediate medical attention. Avoid contact with eyes and mucous membranes; if contact and irritation occur, rinse thoroughly with water. If swallowed, get medical help or contact a poison control centre immediately. This product may increase skin's sensitivity to the sun and particularly the possibility of sunburn. Please limit exposure to the sun and artificial UV light and apply a sunburn protectant while using this product and for a week afterwards. Avoid sport, swimming or the sauna for two days post treatment. Do not participate in laser or Intense Pulsed Light (IPL) facial treatments for 14 days post treatment. Using topical acne products or other chemical peels at the same time or immediately following use of this product may increase dryness or irritation of the skin. Only one product should be used, unless directed by a health care practitioner. Use caution if the patient suffers from immunosuppression, is taking oral contraceptives or tetracycline, has a recent history of medical or cosmetic treatment/procedure (e.g. laser therapy, surgical procedures, cosmetic filler, microdermabrasion,etc.), smoking, herpes simplex, dermatitis, psoriasis, or any other inflammatory condition in the skin area to be treated (as these may have an impact on wound healing).
Originaltext auf Französisch.
Produktdaten
- Andere Namen
- Alumier MD 20% Salicylic Acid Peel, Alumier MD BHA 20, Alumier MD BHA 20 Peel, BHA 20, BHA 20 Peel
- Inhaber
- Alumier Europe Ltd.
- NPN oder DIN-HM
- 80072016
- Status
- Aktive Lizenz
- Lizenzdatum
- 15. August 2016
- Überarbeitungsdatum
- 24. September 2024
- Form
- Liquide
- Verabreichungsweg
- Topique
- Art des Antrags
- Non traditionnelle
Quelle
Amtlicher Health-Canada-Eintrag, Zulassung 80072016
Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise, abgerufen am 27. Oktober 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Originaltext auf Englisch.
Originaltext auf Französisch.
Die unter demselben Namen in Europa verkaufte Rezeptur kann abweichen. Diese Angaben ersetzen keinen ärztlichen oder pharmazeutischen Rat.
Liste in der amtlichen Überarbeitung vom (Register: Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise).
Ist eine Angabe zu diesem Produkt falsch oder veraltet, ob Sie Leser oder Marke sind? Schreiben Sie an contact@compoatlas.com: Jede Korrektur wird im Korrekturprotokoll veröffentlicht.